Core Viewpoint - Yifan Pharmaceutical stated that according to current accounting standards, recognized impairment of intangible assets cannot be reversed, but the company will continue to strive to further explore the market value of the product [2] Group 1 - Yifan Pharmaceutical has acknowledged the impairment of intangible assets and clarified that it cannot be reversed under existing accounting regulations [2] - The company is committed to enhancing the market value of its products despite the impairment [2]

（记者 王晓波） 每经头条（nbdtoutiao）——中国无人驾驶"军团"，"武装"阿布扎比 每经AI快讯，西王食品1月30日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润亏损8.8亿 元~13.2亿元。基本每股收益-1.22元~-0.82元。上年同期归属于上市公司股东的净利润约-4.44亿元。基 本每股收益-0.41元。2025年业绩变动的主要原因为原材料乳清蛋白的价格不断上涨以及日益加剧的竞 争压力，导致运动营养板块业绩不及预期。本着谨慎性原则，公司预计计提无形资产减值损失约9.5亿 元~15亿元人民币，最终减值金额需依据公司聘请的具备相关资格的审计机构进行审计后确定。 ...

近日，中国中药发布公告称，预计2025年本集团将由盈转亏，亏损净额区间预估约为3.5亿元至5亿元， 而上年同期的盈利净额约为2077万元。同时，本期经调整盈利净额预计同比下降45%至55%，上年同期 约为6.36亿元。 董事会表示，上述事项不会对本集团的持续经营能力产生不利影响，并强调所提及的经调整盈利净额并 未在香港财务报告准则中界定。股东及潜在投资者应注意本公告所载信息为初步评估，最终业绩公告预 计于2026年3月底前发布。 亏损的主要原因包括中药配方颗粒业务收入规模及盈利能力下降。此外，本期商誉减值、无形资产减值 及信用减值增加。 （中国中药公告） (编辑：杨燕 林辰) ...

中国中药(00570)跌超4%，截至发稿，跌4.57%，报2.09港元，成交额1129.92万港元。 本期由盈转亏主要原因为：中药配方颗粒业务受集采业务占比提高、市场竞争加剧等影响，收入规模及 盈利能力下降;及本期商誉减值、无形资产减值及信用减值增加;及经调整溢利净额为扣除以下各项影响 后的溢利净额：商誉及相关资产组减值;及部分附属公司补缴税款。 消息面上，中国中药公布，预期集团截至2025年12月31日止年度由盈转亏，亏损净额区间预计约为人民 币3.50亿元至5亿元，上年同期溢利净额约为人民币2077万元；及本期经调整溢利净额同比下降45%至 55%，上年同期约为人民币6.355亿元。 ...

格隆汇1月27日丨东星医疗(301290.SZ)公布，预计2025年归属于上市公司股东的净利润-4,500万元 ～-3,200万元，扣除非经常性损益后的净利润-7,200万元～-5,100万元。1、报告期内，受市场竞争加剧 和客户需求放缓的影响，公司吻合器零部件、医疗设备相关业务收入有所下降，致使主营业务整体毛利 较上年同期有所减少；2、根据《企业会计准则第 8 号——资产减值》及相关会计政策规定，基于谨慎 性原则，结合对全资子公司江苏孜航精密五金有限公司 2025 年度及未来经营业绩、盈利能力的分析， 公司对截至 2025 年 12 月 31 日的资产组进行了减值测试。经初步测算，公司预计2025 年度计提商誉减 值准备金额约为 9,790.94 万元，计提无形资产减值准备的金额约为562.92 万元，减值准备金额合计约为 10,353.86 万元。本次业绩预告情况已考虑拟计提资产减值准备对公司净利润的影响。截至本公告披露 日，上述资产减值测试工作尚在进行中，最终资产减值准备计提金额将由公司聘请的具备证券期货从业 资格的评估机构及审计机构进行评估和审计后确定。 ...

董事会认为：集团本期由盈转亏主要原因为：中药配方颗粒业务受集采业务占比提高、市场竞争加剧等 影响，收入规模及盈利能力下降;及本期商誉减值、无形资产减值及信用减值增加;及经调整溢利净额为 扣除以下各项影响后的溢利净额：商誉及相关资产组减值;及部分附属公司补缴税款。 中国中药(00570)发布公告，预期集团截至2025年12月31日止年度由盈转亏，亏损净额区间预计约为人 民币3.50亿元至5亿元，上年同期溢利净额约为人民币2077万元;及本期经调整溢利净额同比下降45%至 55%，上年同期约为人民币6.355亿元。 ...

格隆汇1月27日丨中国中药(00570.HK)公告，根据集团截至2025年12月31日止年度(「本期」)的未经审 核综合管理账目初步评估，预期集团(a)本期由盈转亏，亏损净额区间预计约为人民币3.5亿元至人民币5 亿元，上年同期溢利净额约为人民币2077万元；及(b)本期经调整溢利净额同比下降45%至55%，上年同 期约为人民币6.36亿元。 根据董事会目前可获得的资料，董事会认为：(a)集团本期由盈转亏主要原因为：(i)中药配方颗粒业务 受集采业务占比提高、市场竞争加剧等影响，收入规模及盈利能力下降；及(ii)本期商誉减值、无形资 产减值及信用减值增加；及(b)经调整溢利净额为扣除以下各项影响後的溢利净额：(i)商誉及相关资产 组减值；及(ii)部分附属公司补缴税款。 ...

Core Viewpoint - Dongning Bio has submitted its listing application for the third time, aiming to provide comprehensive solutions in the life sciences sector, focusing on bioprocessing and laboratory products and services [1][3]. Financial Performance - Revenue for Dongning Bio during the reporting periods (2023 to 2025) was 814.08 million yuan, 842.88 million yuan, and 657.75 million yuan, respectively, with profits of -315 million yuan, -27.5 million yuan, and 14.26 million yuan, indicating a recent turnaround to profitability [3][4]. - The bioprocessing solutions segment accounted for 77% of total revenue in 2023, with reagents and consumables being the primary revenue driver, contributing 44.1%, 47%, and 55.4% in respective periods [3][4]. Business Segments - The company operates two main business lines: bioprocessing solutions and laboratory products and services, with the former being the larger contributor to revenue [1][3]. - The overseas revenue doubled in the first three quarters of 2025, rising from 53.8 million yuan to 112.41 million yuan, increasing its share of total revenue from 9.8% to 17.1% [5][6]. Major Clients and Shareholders - WuXi Biologics, a major shareholder with a 19.75% stake, is also the largest client, contributing 14.9%, 10.9%, and 12.1% of total revenue during the reporting periods [8][10]. - Revenue from the top five clients accounted for 31.1%, 23.9%, and 32.0% of total revenue, indicating a reliance on a concentrated client base [8]. Acquisitions and Goodwill - Since 2020, Dongning Bio has acquired several companies in the bioprocessing and laboratory services sector, leading to a goodwill value of 843 million yuan as of September 30, 2025, which may face impairment risks [10][11]. - The company must estimate future cash flows from acquired subsidiaries to assess goodwill impairment, which could negatively impact financial conditions if assumptions are not met [13].

Core Viewpoint - The company, Huakong Kante (01312.HK), reported a significant increase in net loss for the six months ending June 30, 2025, primarily due to challenges in its fitness franchise business and economic uncertainties [1] Financial Performance - The group's revenue and gross profit for the period were approximately HKD 452.7 million and HKD 254.6 million, representing a decline of about 1.3% and 8.1% respectively compared to the same period in 2024 [1] - The net loss for the group was approximately HKD 321.4 million, a substantial increase from a net loss of approximately HKD 4.5 million in 2024 [1] - Basic loss per share was approximately HKD 5.06, compared to earnings of approximately HKD 0.09 per share in 2024 [1] Business Challenges - The increase in net loss was attributed to a series of changes in the performance of the fitness franchise business, which faced slow recovery due to economic uncertainties and intensified competition [1] - The company's joint venture operating in Taiwan encountered operational difficulties and financial constraints, contributing to the financial losses [1] Impairment Losses - The group recorded significant impairment losses, including: - Expected credit loss model impairment of financial assets amounting to approximately HKD 159.0 million, compared to HKD 25.5 million in 2024 [1] - Impairment loss on intangible assets of approximately HKD 123.9 million, compared to HKD 13.6 million in 2024 [1] - Goodwill impairment loss in the fitness business segment of approximately HKD 88.4 million, whereas there was no such loss recorded in 2024 [1]

Group 1 - The company, Junma Semiconductor (08490), expects a loss attributable to shareholders of approximately HKD 30.4 million for the period ending June 30, 2025, compared to a profit of about HKD 2.2 million in the same period of 2024 [1] - The primary reasons for the shift from profit to loss include impairment losses on certain intangible assets and a decline in revenue and gross margin for the company's products during this period [1] - The impairment losses recognized during this period are attributed to intense competition and a general decrease in consumer demand in the first half of 2025, leading to underperformance of several products [1] Group 2 - The impairment is a non-cash expense and will not affect the overall operations of the company during this period [1] - The company's profit before interest, tax, depreciation, and amortization (EBITDA) for this period is approximately HKD 2.5 million, compared to about HKD 18.7 million for the period ending June 30, 2024 [1]